Skip to main content
The NCI Community Hub will be retiring in May 2024. For more information please visit the NCIHub Retirement Page:https://ncihub.cancer.gov/groups/ncihubshutdown/overview
close

Tags: clinical trials

Presentations (1-2 of 2)

  1. Regulatory Challenges and Opportunities for Digital Pathology

    29 Nov 2016 | | Contributor(s):: Nick Anderson

    FDA has cleared or approved a number of digital pathology devices for different intended uses, such as digital read and image analysis of immunohistochemically stained tissue slides, classification and enumeration of peripheral blood cells, and initial screening of cervical cytology slides. ...

  2. The Good,The Bad and The Ugly for Clinical Markers: Possibilities For the Future

    30 Jun 2015 | | Contributor(s):: Kim Jessup

    Markers are becoming more important in NCI-supported clinical trials.  These trials are becoming increasingly oriented toward precision medicine. This presentation provides an overview of a database for markers used in NCI Trials as well as definitions of markers and their uses in trials....